ABIN953283

antibody from antibodies-online

Targeting: MAFB KRML

Provider product page for ABIN953283

Western blot

Flow cytometry

Antibody data

Antibody Data
Antigen structure
References [5]
Comments [0]
Validations
Western blot [1]
Flow cytometry [1]

Submit

Product number: ABIN953283 - Provider product page
Provider: antibodies-online
Product name: anti-V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog B (Avian) (MAFB) (C-Term) antibody
Antibody type: Polyclonal
Description: Protein A column, followed by peptide affinity purification
Reactivity: Human
Host: Rabbit
Epitope: C-Term
Vial size: 0.4 mL
Storage: Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Handling: Avoid repeated freezing and thawing.

MAFB protein structure - ABIN953283 shown in red.

Submitted references A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4.

Beaty TH, Murray JC, Marazita ML, Munger RG, Ruczinski I, Hetmanski JB, Liang KY, Wu T, Murray T, Fallin MD, Redett RA, Raymond G, Schwender H, Jin SC, Cooper ME, Dunnwald M, Mansilla MA, Leslie E, Bullard S, Lidral AC, Moreno LM, Menezes R, Vieira AR, Petrin A, Wilcox AJ, Lie RT, Jabs EW, Wu-Chou YH, Chen PK, Wang H, Ye X, Huang S, Yeow V, Chong SS, Jee SH, Shi B, Christensen K, Melbye M, Doheny KF, Pugh EW, Ling H, Castilla EE, Czeizel AE, Ma L, Field LL, Brody L, Pangilinan F, Mills JL, Molloy AM, Kirke PN, Scott JM, Arcos-Burgos M, Scott AF
Nature genetics 2010 Jun;42(6):525-9

The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3.

Kim H, Seed B
Nature immunology 2010 Aug;11(8):743-50

TFE3 transcription factor regulates the expression of MAFB during macrophage differentiation.

Zanocco-Marani T, Vignudelli T, Parenti S, Gemelli C, Condorelli F, Martello A, Selmi T, Grande A, Ferrari S
Experimental cell research 2009 Jul 1;315(11):1798-808

Common variants at 30 loci contribute to polygenic dyslipidemia.

Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J, de Bakker PI, O'Donnell CJ, Chambers JC, Kooner JS, Hercberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins R, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordovas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA
Nature genetics 2009 Jan;41(1):56-65

OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.

Våtsveen TK, Tian E, Kresse SH, Meza-Zepeda LA, Gabrea A, Glebov O, Dai HY, Sundan A, Kuehl WM, Børset M
Leukemia research 2009 Dec;33(12):1670-7